AIM ImmunoTech Inc. has entered into two exchange agreements with Streeterville Capital, LLC, converting approximately $400,000 of a promissory note into shares of common stock. This conversion results in the issuance of 1,749,434 shares at an average price of $0.228 per share. The stockholder's approval was obtained for this transaction
Company Information
Company
AIM ImmunoTech
Location
Ocala, Florida, United States
About
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
Don't miss AIM ImmunoTech's next move
Get an email the moment AIM ImmunoTech raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Verified contacts21 people are listed at AIM ImmunoTech. We don't have their email yet.
Predictive Intelligence
Strategic
ML-powered predictions for AIM ImmunoTech's next move
OcalaBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical